← Back to headlines
Merck Beats Q1 Estimates on Keytruda Sales Growth
Merck reported stronger-than-expected first-quarter sales and profit, primarily fueled by robust demand for its blockbuster cancer drug Keytruda. Despite this, the company narrowed its full-year outlook and noted declines in sales for some other products.
30 Apr, 10:32 — 30 Apr, 12:41
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (56/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoocnbc
Center1
Center (1)
Reuters
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US3Intl1
Sources
Showing 3 of 4 sources
ReutersVery High101d ago
Merck beats quarterly sales expectations as Keytruda fuels growth - Reuters
Merck beats quarterly sales expectations as Keytruda fuels growth Reuters
Read full article →cnbcMostly Factual101d ago
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Read full article →YahooMostly Factual101d ago
Merck tops Q1 estimates on strong oncology demand; shares rise
Read full article →Coverage Timeline
First report: cnbc · 30 Apr, 10:32|Full coverage: 4 · 2h|Window: 2h
Left-leaningCenterRight-leaning
